SV

Street Verdict

Analyst Scorecard

SYNGENE · NSE

Syngene International Limited

₹451.7

+3.28% (+₹14.35)

Prev. close

₹437.35

Volume

25,57,651

Delivery %

44.2%

As of

20 Nov 2026

Price history

₹451.7+₹47.6 (+11.78%) · 3M
18 Aug 2026 → 20 Nov 2026
36038040042044018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 2 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Syngene International Limited

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Details

Sector

Healthcare

Industry

Diagnostics & Research

CEO

Mr. Siddharth Mittal BCom, CA, CPA

Headquarters

Bengaluru

Employees

6,692

Key stats

Market cap

₹16,779.89 Cr

P/E ratio (TTM)

90.4

Dividend yield

0.31%

EPS (TTM)

₹4.62

Beta (1Y · daily vs NIFTY 50)

0.69

Beta (5Y · monthly vs NIFTY 50)

1.20

Shares float

17.60 Cr

EPS · quarter ended Sept 2026

₹0.80

Upcoming earnings

20 Jan 2027

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0%5%10%15%20%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

051015₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0112₹0%10%20%30%30 Jun 2230 Jun 2328 Jun 2427 Jun 2525 Jun 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-50%-25%0%25%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr2500 Cr5000 Cr7500 Cr₹0×0.2×0.4×0.6×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr2500 Cr5000 Cr7500 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

0 Cr250 Cr500 Cr750 Cr1000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹2,184.30 Cr₹2,604.20 Cr₹3,192.90 Cr₹3,488.60 Cr₹3,642.40 Cr₹3,738.70 Cr
EBITDA
₹771.40 Cr₹818.20 Cr₹1,005.30 Cr₹1,093.90 Cr₹1,145.60 Cr₹912.60 Cr
₹404.90 Cr₹395.80 Cr₹464.40 Cr₹510.00 Cr₹496.20 Cr₹316.70 Cr
Diluted EPS
₹10.11₹9.82₹11.51₹12.69₹12.34₹7.87

EBITDA for Mar 2021 could not be checked against the company's own annual report: this page shows ₹771.40 Cr while the annual report gives ₹736.40 Cr (4.5% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹699.50 Cr) is left blank here too, rather than shown from only one of the two sources.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
——₹5,831.00 Cr₹6,151.60 Cr₹6,795.90 Cr₹7,054.70 Cr
——₹815.20 Cr₹555.20 Cr₹577.90 Cr₹458.40 Cr
Stockholders' equity
——₹3,618.00 Cr₹4,257.70 Cr₹4,726.80 Cr₹4,839.10 Cr

Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹701.20 Cr₹580.60 Cr₹823.50 Cr₹1,042.10 Cr₹1,167.60 Cr₹915.20 Cr
Investing cash flow
₹-628.10 Cr₹-611.50 Cr₹-656.40 Cr₹-495.60 Cr₹-744.70 Cr₹-860.40 Cr
₹58.00 Cr₹-31.30 Cr₹-342.50 Cr₹-551.40 Cr₹-141.80 Cr₹-215.00 Cr
Capital expenditure
₹-446.50 Cr₹-475.50 Cr₹-518.30 Cr₹-510.80 Cr₹-770.10 Cr₹-368.20 Cr
End cash position
₹323.30 Cr₹261.80 Cr₹89.50 Cr₹85.70 Cr₹367.10 Cr₹228.60 Cr

Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24–Mar 25(2Q)Jun 25Sep 25Dec 25Mar 26Jun 26
Promoter70.42%70.41%70.41%70.29%64.86%64.86%54.88%54.80%54.79%54.79%54.79%54.72%54.72%52.74%52.68%52.68%52.68%52.68%52.59%
Public28.72%28.87%28.91%28.89%34.65%34.67%44.66%44.60%44.72%44.89%44.90%44.85%44.94%46.97%47.00%47.01%47.02%47.03%46.98%
Employee trusts0.86%0.72%0.68%0.83%0.49%0.47%0.46%0.60%0.48%0.32%0.31%0.43%0.34%0.29%0.31%0.30%0.29%0.29%0.43%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Syngene International Limited₹16,341.81 Cr₹417.588.03.386.5%0.09+2.8%-35.4%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

SYNGENE

We Think You Can Look Beyond Syngene International's (NSE:SYNGENE) Lackluster Earnings

Simply Wall St · 17 days ago

SYNGENE

Syngene Reports 13% Quarterly Revenue Growth, Boosts EBITDA Margin to 18% in Q2 FY27

Medical Dialogues · 18 days ago